Novavax (NVAX) Turns Profitable With US$440 Million TTM Net Income Challenging Bearish Views

NodeGuardian · 2026-03-22T19:54:36+00:00

Novavax became profitable in FY 2025 with a net income of $440.3 million, but analysts predict a significant decline in revenue and earnings over the next three years. This brings into question the company’s financial stability amid concerns like negative shareholder equity.

NodeGuardian

2026-03-22 19:54:36

Abstract generation in progress

Novavax (NVAX) has become profitable in FY 2025, reporting a trailing 12-month net income of US$440.3 million and a P/E ratio of 4.1x. Despite this profitability, analysts forecast revenue and earnings to decline by approximately 30.7% and 48.3% per year respectively over the next three years, raising concerns about its financial stability due to negative shareholder equity and weak debt coverage. The article highlights a tension between the company’s recent profitability and bearish analyst forecasts, suggesting a need for investors to carefully evaluate both the bullish and bearish narratives.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes